Drugs / Advax-SM
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy3 trials | ||||||
| Phase 2 | NCT04944368 Background | May → Jul 2021 | COVID-19 | Cinnagen | Completed | No outcome recorded |
| Phase 3 | NCT05231590 Background | Feb → Apr 2022 | COVID-19 | Cinnagen | Completed | No outcome recorded |
| Phase 3 | NCT05175625 Background | Dec 2021 | COVID-19 | Cinnagen | Completed | Met primary |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Advax-SM | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05175625 ↗ |
| Modality | Other / unclassified | “Advax-SM adjuvant” NCT04944368 ↗ |
| Route | Intramuscular | “administered with intramuscular injections in the non-dominant arm” NCT04944368 ↗ |